An Experimental New Drug for Stiff Person Syndrome Restores Mobility

Why It Matters

The breakthrough offers the first disease‑modifying option for SPS, a rare autoimmune disorder with no approved therapies, and could open the door for CAR‑T approaches in other autoimmune diseases.

Key Takeaways

• miv‑cel showed mobility gains in 26‑patient Phase II trial.
• 8 of 12 walkers eliminated need for walking aids post‑treatment.
• Therapy uses CAR‑T to delete B cells, resetting antibody production.
• Low white‑blood‑cell count was most common serious adverse event.
• FDA filing expected first half 2026, could be first autoimmune CAR‑T.

Pulse Analysis

Stiff person syndrome, affecting roughly 5,000 Americans, has long been a therapeutic orphan, with patients relying on symptomatic drugs and off‑label immune therapies that provide limited relief. The condition’s hallmark—autoantibody‑driven muscle rigidity and painful spasms—has made it a prime candidate for innovative immunologic interventions. By targeting the root cause rather than merely managing symptoms, miv‑cel represents a paradigm shift that could dramatically improve quality of life for a patient population that has historically faced progressive disability.

Kyverna’s miv‑cel adapts the CAR‑T platform, originally pioneered for cancer, to eradicate B‑cells, the body’s antibody factories. In the Phase II study, a single infusion led to measurable gains in walking speed and, notably, a 67% reduction in walking‑aid dependence among participants. While the therapy was generally well‑tolerated, a transient drop in white‑blood‑cell counts emerged as the primary safety signal, echoing known risks of B‑cell depletion. Ongoing monitoring will determine whether repeat dosing is necessary or if a one‑time infusion can sustain remission.

If the FDA grants approval later this year, miv‑cel would become the first CAR‑T product for an autoimmune disease, setting a precedent for a new class of cellular therapies. The success could accelerate investment in similar approaches for conditions like multiple sclerosis and lupus, reshaping the biotech landscape. Moreover, a breakthrough in SPS may spur payer coverage discussions and drive pricing models for high‑cost, curative‑intent cell therapies, influencing how the healthcare system evaluates value in rare disease treatments.